Please login to the form below

Not currently logged in
Email:
Password:

risankizumab

This page shows the latest risankizumab news and features for those working in and with pharma, biotech and healthcare.

AbbVie lauds head-to-head win for Skyrizi versus Cosentyx

AbbVie lauds head-to-head win for Skyrizi versus Cosentyx

Skyrizi. The head-to-head study pitted IL-23 antagonist Skyrizi (risankizumab) against Novartis’ blockbuster IL-17 inhibitor Cosentyx (secukinumab) – which has sales currently running at around $1bn a quarter – and

Latest news

More from news
Approximately 3 fully matching, plus 24 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...

Infographics